CD276 and neoplasm: Kasten et al. showed that preclinical radioimmunotherapy in ovarian cancer using CD276 antibodies radiolabeled with 212Pb α-particles targets tumor cells and the vasculature, thus, showing promising effects along with low toxicity [32].